Duality Biotherapeutics (HKG:9606) said updated data from an early-stage study of DB-1311/BNT324 showed signs of activity in patients with advanced prostate cancer who had already received multiple prior treatments, according to a Hong Kong bourse filing Tuesday.

Of the 58 patients who could be assessed for tumor response, 34.5% had a confirmed objective response rate, indicating their cancer shrank or disappeared.

Meanwhile, the disease control rate, a measure of patients whose cancer shrank or stabilized after treatment, stood at nearly 88%.

The firm said it would present the data at the American Society of Clinical Oncology Genitourinary Cancers Symposium 2026.

Shares of the company were down nearly 3% in recent morning trade.